Projects in Clinical Development

Product

Indication

Preclinic/
Research

Clinical Phase

Approval

Marketed

III

Eligard^® 1)

Veregen® (Polyphenon
E Ointment) ^® 2)

Genital Warts

Actinic Keratosis ³⁾

EndoTAG^®-1

Pancreatic Cancer

Breast Cancer

Additional solid tumors

RhuDex^®

Rh. Arthritis

oHSV (NV1020)

Colon Liver Metastases

Chance of reaching the market⁴

10-30%

30-60%

60-80%

80-90%

¹ European marketing rights acquired from QLT USA Inc.(formerly Atrix). Marketing partnership with Astellas Pharma Ltd.
² Marketing partnership with Nycomed for the US market und Juste S.A.Q.F., for Spain and Portugal.
³ Precursors of a specific kind of skin cancer.
⁴ Industrial average, source: Ernst&Young, 2009.